Enovis has been the most acquisitive orthopedic company in recent years, with eight transactions since the beginning of 2020.
SEAL specializes in foot and ankle external fixation. SEAL’s systems have produced excellent results in the treatment of foot and ankle deformities, fractures and fusions.
Xtant acquired the Coflex and Cofix product lines from Surgalign for a total consideration of $17 million.
The company’s pending acquisition of NuVasive is about increasing operational capacity and vertical integration.
The combines will combine in an all-stock merger to create the 7th largest orthopedic company overall and 2nd largest spine player.
The move strengthens Tyber Medical’s international presence and adds a range of product options in the MIS bunion, PEEK hammertoe and screw fixation arenas.
Mid-tier companies Orthofix and SeaSpine merged in early January 2023 to become the ninth-largest company in orthopedics.
The acquisition expands Companion Spine’s portfolio with Backbone’s LISA lumbar implant for stiffness augmentation.
The combined Orthofix will have orthopedic sales that approach $700 million for 2022, making it the ninth largest player in the industry.
After peaking in 2020, orthopedic M&A volume declined more than 40% in 2021 and dropped another 12% in 2022.
The acquisition includes the TAPESTRY biointegrative implant for tendon healing and TAPESTRY RC for rotator cuff repair.
The combined organization creates the eighth-largest spine company, with a portfolio spanning trauma, orthobiologics and bone growth therapies.
CurveBeam and StraxCorp completed their previously-announced merger. Under the new name CurveBeam AI, the company expands CurveBeam’s point-of-care imaging solutions…
The combined organization creates the eighth-largest spine company, bolstered by a well-balanced portfolio spanning trauma, orthobiologics and bone growth therapies.
CurveBeam AI expands CurveBeam’s financially viable point-of-care imaging solutions into the bone health space
The resulting business will broaden and derisk Bone Therapeutics’ portfolio thata targets a broad array of inflammatory and orthopedic indications.
Through this acquisition, CONMED acquires next-generation bioinductive collagen scaffold technology for application in sports medicine soft tissue healing.